Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GALECTIN THERAPEUTICS INC Director's Dealing 2021

Nov 1, 2021

33422_dirs_2021-11-01_554e2334-64d7-4ea5-95f9-b9c9b3dbf400.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2021-10-29

Reporting Person: FREEMAN KEVIN D (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-10-29 Common Stock P 2000 $3.17 Acquired 40000 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 23469 Direct
Common Stock 16000 Indirect

Footnotes

F1: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.